Retrometabolic drug design: principles and recent developments.
Abstract: Retrometabolic drug design incorporates two major systematic approaches: the design of soft drugs (SDs) and of chemical delivery systems (CDSs). Both aim to design new, safe drugs with an improved therapeutic index by integrating structure-activity and -metabolism relationships; however, they achieve it by different means: whereas SDs are...

Computational materials science: from chemical reactions to drug design.
The significance of computer simulations has become more recognizable in the fields of Physics, Chemistry and Biology. Ab-Initio calculations that are based on Density Functional Theory (DFT) have provided useful simulations and the ability for scientists to calculate accurately a number of physical and chemical properties, some of which...

ARGENTA/AMEDIS FORM DRUG DISCOVERY COLLABORATION.
Argenta Discovery Ltd, Harlow, U.K. has entered into a drug discovery collaboration with Cambridge-based Amedis Pharmaceuticals Ltd. Argenta will work to create a series of highly novel small molecule inhibitors of a selected number of medicinally relevant protease enzymes. The work is focused on Amedis' broad patent...

ARGENTA/NOVARTIS SIGN TWO-YEAR DRUG DISCOVERY PACT.
Argenta Discovery Ltd, Harlow, UK, a contract drug discovery and respiratory drug development company, has entered into a two-year drug discovery collaboration with Novartis. Under the terms of the agreement Argenta's medicinal chemistry teams will collaborate with Novartis' scientists in the search for new disease therapies. The deal also...

ArQule and Nanodesign Enter into Collaboration for Novel Drug Design Technology.
WOBURN, Mass., and GUELPH, Ontario, Jan. 16 /PRNewswire/ -- ArQule, Inc. (Nasdaq: ARQL) and Nanodesign Inc. ("Nanodesign"), a wholly owned subsidiary of SignalGene Inc. (Toronto: SGI), announced today that they have entered into a collaboration to develop and apply a novel compound design platform for drug discovery....

Market booms for biomedical nanoscale devices.
The worldwide market for nanoscales devices used for biomedical purposes is expected to grow at an average annual growth rate of 34.5% in the period 2002-2007, becoming a one billion dollar industry by that date, predicts a new report from Business Communications Co Inc (BCC). The report...

Tripos Introduces DiscoveryStudio(TM) Software System With Integrated Microsoft VBA.
New Software Provides Infinite Flexibility for Desktop Molecular Analysis and 3-D Visualization ST. LOUIS, March 26 /PRNewswire/ -- Tripos, Inc., (Nasdaq: TRPS) a leading provider of discovery research software and services, announced today that it will preview DiscoveryStudio(TM), a new software system that...

Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence.
ST. JOSEPH, Mich., Jan. 20 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Department of Energy's Pacific Northwest National Laboratory (PNNL) has become a certified GeneGo Center of Excellence. PNNL researchers will have institution-wide access to GeneGo's MetaCore data analysis suite, training and...

Jubilant Biosys Launches Legend NGSS(TM) Advanced Software Solution for High-Throughput Drug Molecule Screening.
NOIDA, India, Jan. 21 /PRNewswire/ -- Jubilant Organosys Ltd, headquartered in Noida near New Delhi, announced today that its subsidiary Jubilant Biosys Ltd., based in Bangalore, has developed a next generation screening solution, Legend NGSS(TM), that will further enable the process of high throughput screening, accelerating global drug discovery....

University of Glasgow Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program.
ST. JOSEPH, Mich., Jan. 27 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Nicol Keith of the University of Glasgow will join the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for...